JP2019122266A - Screening method and kit of heel roughening suppression agent - Google Patents

Screening method and kit of heel roughening suppression agent Download PDF

Info

Publication number
JP2019122266A
JP2019122266A JP2018003097A JP2018003097A JP2019122266A JP 2019122266 A JP2019122266 A JP 2019122266A JP 2018003097 A JP2018003097 A JP 2018003097A JP 2018003097 A JP2018003097 A JP 2018003097A JP 2019122266 A JP2019122266 A JP 2019122266A
Authority
JP
Japan
Prior art keywords
keratin
substance
roughening
model
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018003097A
Other languages
Japanese (ja)
Other versions
JP7059015B2 (en
Inventor
咲子 浅井
Sakiko Asai
咲子 浅井
美穂 森田
Yoshio Morita
美穂 森田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naris Cosmetics Co Ltd
Original Assignee
Naris Cosmetics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naris Cosmetics Co Ltd filed Critical Naris Cosmetics Co Ltd
Priority to JP2018003097A priority Critical patent/JP7059015B2/en
Publication of JP2019122266A publication Critical patent/JP2019122266A/en
Application granted granted Critical
Publication of JP7059015B2 publication Critical patent/JP7059015B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

To provide a method for screening an effective substance for improving roughening unique to a heel.SOLUTION: There are provided a method for screening a substance including a heel roughening suppression effect including steps (A)-(D) and an evaluation kit using the method, the step (A) is a step in which a cultivation skin model and a test substance are made to coexist, the step (B) is a step for applying a load to the cultivation skin model, the step (C) is a step for extracting a gene or protein from the cultivation skin model, and the step (D) is a step for determining a substance having a heel roughening suppression effect with at least one gene selected from keratin 1, keratin 10 or protein expression amount and a gene or protein expression amount of involucrin, as indexes.EFFECT: As an effect, the effective substance for improving roughening unique to a heel can be screened, according to the screening method and the kit.SELECTED DRAWING: Figure 2

Description

本発明は踵荒れ抑制効果を有する素材のスクリーニング方法及びそのためのキットに関する。具体的には、培養表皮モデルのケラチン1、ケラチン10より選択された1つ以上の遺伝子及び/又はタンパクの発現量と、インボルクリン遺伝子及び/又はタンパクの発現量を指標とした荷重刺激によって生じる踵荒れ抑制効果を有する素材のスクリーニング方法及びそのためのキットに関する。 The present invention relates to a method of screening a material having a roughening inhibitory effect and a kit therefor. Specifically, the expression level of one or more genes and / or proteins selected from keratin 1 and keratin 10 in the cultured epidermis model and the load stimulation using the expression level of involucrin gene and / or protein as an index The present invention relates to a method of screening a material having a roughening inhibitory effect and a kit therefor.

足裏で起こる様々なトラブルの中でもかさつきや粉ふき、ひび割れといった症状を伴う踵荒れは季節や性別に関わらず日常的に好発することが知られている。美容的観点から見た目の美しさを損なうだけでは無く、痛みを伴う場合、歩行に際して困難や不快感を引き起こすため、健康に害を及ぼす可能性もあり、根本的な解決方法の提案が望まれている。しかしながら、踵荒れが起こるメカニズムについて詳細に検討して報告した例はほとんど無く、根本的な解決手段はあまり知られていない。 Among various troubles that occur in the sole, it is known that roughness with symptoms such as bulkiness, dusting, and cracking usually occur everyday regardless of season or gender. Not only does it impair the beauty of the appearance from a cosmetic point of view, but also causes pain and discomfort during walking when it is accompanied by pain, which may be harmful to health, and a proposal for a fundamental solution is desired. There is. However, there have been few examples that have investigated and reported in detail the mechanism by which roughening occurs and the fundamental solution is not well known.

従来、踵荒れに対する対策としてはピーリング(特許文献1)や研削器(特許文献2)などを用いた角質除去、保湿(特許文献3)や角層柔軟効果(特許文献4)を有する化粧料の使用など様々な手段が提案されているが、こうした対策は踵荒れで生じる症状を軽快させることを目的とするもので、踵荒れの発生原因に即した手段ではないため、その効果は一時的で、再発するといった問題もあった。 Heretofore, as a countermeasure against roughening, a cosmetic having exfoliating horny using a peeling (patent document 1) or a grinder (patent document 2) or the like, moisturizing (patent document 3) or a horny layer softness effect (patent document 4) Although various means such as use have been proposed, these measures are aimed at alleviating the symptoms caused by roughening and are not in line with the causes of roughening, so their effects are temporary. There was also a problem that it recurred.

皮膚は大きく分けて3層構造をとり、外側から表皮、真皮、皮下組織となっているが、角層は表皮の中で最も外側に位置し、主に死んだ細胞と水を保持した角層細胞間脂質から構成されている。角層は、体内からの過剰な水分蒸散を防ぐと共に、外界からの多様な刺激や異物の浸入を防御する役割などを担っており、この様な働きはバリア機能と呼ばれている。 The skin is roughly divided into three layers, from the outside the epidermis, the dermis, and the subcutaneous tissue, but the stratum corneum is the outermost layer in the epidermis and mainly contains dead cells and water. It is composed of intercellular lipids. The stratum corneum plays a role of preventing excessive water evaporation from the body and preventing various kinds of external stimuli and infiltration of foreign matter, and such function is called a barrier function.

表皮の最下部に位置する基底細胞から、細胞分裂により生まれた細胞(ケラチノサイト)が徐々に押し上げられ、必要な物質を生産しながら分化、成熟することで角層細胞(角質細胞)へ至るまでの過程は角化と呼ばれる。表皮では、精密な基底細胞の細胞分裂と角化のバランスの調整により、正常性が保たれている。角化に伴って異なるケラチン分子種が発現し、例えば基底細胞ではケラチン5(K5)、ケラチン14(K14)、有棘細胞ではケラチン1(K1)、ケラチン10(K10)などが順次発現する。さらに、終末角化(終末分化)の過程では角層細胞を強靭な構造にしている辺縁帯(コーニファイド・エンベロープ)がインボルクリン(IVL)やロリクリンといったタンパクがトランスグルタミナーゼIによって架橋、不溶化することで形成される。辺縁帯は安定な角質細胞構造の構築に寄与しており、角層がバリアとして機能するための重要な構造である。したがって、K5、K14、K1、K10、IVLなどの量を指標として、角化の程度を評価することができることは知られていた。 From the basal cells located at the lowermost part of the epidermis, the cells (keratinocytes) born by cell division are gradually pushed up, and while differentiating and maturing while producing the necessary substances, they reach up to the stratum corneum cells (keratinocytes) The process is called keratinization. In the epidermis, normality is maintained by precisely adjusting the balance of cell division and keratinization of basal cells. With keratinization, different keratin molecular species are expressed, for example, keratin 5 (K 5), keratin 14 (K 14) in basal cells, keratin 1 (K 1), keratin 10 (K 10) etc. in spiny cells. Furthermore, in the process of terminal keratinization (terminal differentiation), a marginal zone (cornified envelope) that makes the stratum corneum cell tough structure (cross-linked and insolubilized proteins such as involucrin (IVL) and loricrin by transglutaminase I. It is formed by The marginal zone contributes to the construction of a stable keratinocyte structure and is an important structure for the stratum corneum to function as a barrier. Therefore, it has been known that the degree of keratinization can be evaluated using the amounts of K5, K14, K1, K10, IVL, etc. as an index.

たとえば、表皮細胞に対する角化亢進剤の適用は、ケラチン1、ケラチン10、インボルクリンの発現促進を誘導し(非特許文献1)、逆に、角化抑制剤の適用は、ケラチン1、ケラチン10、インボルクリンの発現抑制を誘導する(非特許文献2)。
しかしながら、外観上の肌荒れを伴う皮膚疾患やドライスキンにおいては、細胞分裂等の角化の程度以外に関する変化を伴うこともあり、ケラチン1、ケラチン10、インボルクリンのすべての発現量が亢進するものだけではなく、ケラチン1およびケラチン10が減少してインボルクリン発現領域が広がるもの(非特許文献3、4)もあり、踵荒れにおいて、これらの量にどのような変化が生じているかについては、全く知られていなかった。
For example, the application of an agent for promoting keratinization to epidermal cells induces the promotion of expression of keratin 1, keratin 10, and involucrin (Non-patent document 1), conversely, the application of an agent for suppressing keratinization is keratin 1, keratin 10, It induces the suppression of expression of involucrin (Non-patent Document 2).
However, skin diseases and dry skin with rough skin on appearance may be accompanied by changes related to the degree of keratinization such as cell division, and only those whose expression levels of keratin 1, keratin 10 and involucrin are enhanced However, there are some in which keratin 1 and keratin 10 decrease and the involucrin expression area spreads (non-patent documents 3 and 4), and it is completely known about what change has occurred in these amounts in roughening. It was not done.

特開2005−200391号公報JP 2005-200391 A 特開2001−62724号公報JP, 2001-62724, A 特許第3979497号Patent No. 3979497 特開2010−241748号公報JP, 2010-241748, A

Adeline F. Deyrieux et al. Journal of Cell Science. 2007; 120(1): 125-136.Adeline F. Deyrieux et al. Journal of Cell Science. 2007; 120 (1): 125-136. M. Gschwandtner et al. Allergy. 2013; 68(1): 37-47.M. Gschwandtner et al. Allergy. 2013; 68 (1): 37-47. 前島英樹. Clinical Derma. 2013; 15(3): 3-6.Hideki Maejima. Clinical Derma. 2013; 15 (3): 3-6. Akemi Ishida-Yamamoto et al. J Invest Dermatol. 1995; 104(3): 391-395.Akemi Ishida-Yamamoto et al. J Invest Dermatol. 1995; 104 (3): 391-395.

本発明は、上記背景に鑑みてなされたものであり、踵特有の荒れを改善する有効物質をスクリーニングする方法を提供することを課題とする。 The present invention has been made in view of the above background, and an object of the present invention is to provide a method of screening for an effective substance that improves the specific roughness of a sputum.

〔1〕第1発明としては、
次の(A)〜(D)のステップを含む踵荒れ抑制効果を有する物質をスクリーニングする方法。
(A):培養表皮モデルと被験物質を共存させるステップ
(B):培養表皮モデルに荷重を加えるステップ
(C):培養表皮モデルから遺伝子を抽出するステップ
(D):(d−1)及び(d−2)を指標に踵荒れ抑制効果を有する物質を判断するステップ
(d−1):ケラチン1、ケラチン10より選択された少なくとも1つ以上の遺伝子発現量及び/又はタンパク発現量、
(d−2):インボルクリンの遺伝子発現量及び/又はタンパク発現量
〔2〕第2発明としては、第1発明における(D)ステップにおいて、
ケラチン1、ケラチン10より選択された少なくとも1つ以上の遺伝子発現量を減少させ、インボルクリンの遺伝子発現量は変化させない被験物質を踵荒れ抑制効果を有する物質として判断するスクリーニング方法。
〔3〕第3発明としては、
次の(A)〜(D)のステップを含む踵荒れ抑制効果を有する物質をスクリーニングする方法。
(A):培養表皮モデルと被験物質を共存させるステップ
(B):培養表皮モデルに荷重を加えるステップ
(C):培養表皮モデルからタンパクを抽出するステップ
(D):ケラチン1、ケラチン10より選択された少なくとも1つ以上のタンパクの発現量及びインボルクリンのタンパクの発現量を指標に踵荒れ抑制効果を有する物質を判断するステップ
〔4〕第4発明としては、第3発明における(D)ステップにおいて、
ケラチン1、ケラチン10より選択された少なくとも1つ以上のタンパク発現量を減少させ、インボルクリンのタンパク発現量は変化させない被験物質を踵荒れ抑制効果を有する物質として判断するスクリーニング方法。
〔5〕第5発明としては、
次の(A)〜(C)のステップを含む踵荒れ抑制効果を有する物質をスクリーニングする方法。
(A):培養表皮モデルと被験物質を共存させるステップ
(B):培養表皮モデルに荷重を加えるステップ
(C):培養表皮モデルから組織切片を作製し、角層の厚みの変化を指標に踵荒れ抑制効果を有する物質を判断するステップ
〔6〕第6発明としては、
第1発明乃至第5発明の方法を用いた評価キット。
[1] As a first invention,
The method of screening the substance which has the roughening control effect containing the step of following (A)-(D).
(A): A step of coexistence of a cultured epidermal model and a test substance
(B): Step of applying a load to the cultured epidermal model (C): step of extracting a gene from the cultured epidermal model
(D): (d-1) and (d-2) determining the substance having a roughening inhibitory effect with the index (d-1): at least one or more genes selected from keratin 1, keratin 10 Expression level and / or protein expression level,
(D-2): gene expression amount and / or protein expression amount of involucrin [2] As a second invention, in the step (D) of the first invention,
A screening method of decreasing a gene expression level of at least one or more selected from keratin 1 and keratin 10, and judging a test substance which does not change the gene expression level of involucrin as a substance having a roughening inhibitory effect.
[3] As a third invention,
The method of screening the substance which has the roughening control effect containing the step of following (A)-(D).
(A): A step of coexistence of a cultured epidermal model and a test substance
(B): Step of applying a load to the cultured epidermis model (C): step of extracting a protein from the cultured epidermis model
(D): Determining a substance having an anti-corrosion effect based on the expression level of at least one protein selected from keratin 1 and keratin 10 and the expression level of protein of involucrin [4] as a fourth invention Is the step (D) in the third invention,
A screening method of reducing a protein expression amount of at least one or more selected from keratin 1 and keratin 10 and determining a test substance which does not change the protein expression amount of involucrin as a substance having a roughening inhibitory effect.
[5] As a fifth invention,
The method of screening the substance which has the roughening control effect containing the step of following (A)-(C).
(A): A step of coexistence of a cultured epidermal model and a test substance
(B): applying a load to the cultured epidermal model (C): preparing a tissue section from the cultured epidermal model and determining a substance having a roughening inhibitory effect by using a change in thickness of the stratum corneum as an index [6] 6 As an invention,
An evaluation kit using the method of the first to fifth inventions.

本発明による踵荒れ抑制剤のスクリーニング方法及びキットは、踵特有の荒れを改善する有効物質をスクリーニングすることが可能になる。   The screening method and kit of the roughening inhibitor according to the present invention make it possible to screen for an effective substance that improves the roughening peculiar to chewing.

健常群と荒れ群の踵写真(代表例)Photographs of normal and rough groups (typical example) 健常群と荒れ群の体重Weight of normal group and rough group 健常群と荒れ群の皮膚の柔らかさSoftness of normal and rough group skin 健常群と荒れ群の表皮角層水分量Epidermal stratum corneum water content of normal group and rough group 健常群と荒れ群の経表皮水分蒸散量Transepidermal water loss in healthy and rough groups 健常群と荒れ群の角層細胞面積Stratum corneum cell area of normal group and rough group 荷重刺激による細胞生存率への影響Effect of weight stimulation on cell viability 荷重刺激によるケラチン1遺伝子発現量変化Changes in keratin 1 gene expression due to load stimulation 荷重刺激によるケラチン10遺伝子発現量変化Changes in keratin 10 gene expression due to load stimulation 荷重刺激によるインボルクリン遺伝子発現量変化Changes in involucrin gene expression by load stimulation 荷重刺激による角層厚の変化Change of angular layer thickness by load stimulation

本発明における培養表皮モデルは、特に限定されないが、例えば、ヒト正常表皮細胞を重層培養した三次元培養モデルを用いればよく、LabCyte EPI−MODEL(ジャパン・ティッシュ・エンジニアリング)、EPI−200(クラボウ)、EPISKIN(SkinEthic)等を使用することが出来る。   The culture epidermal model in the present invention is not particularly limited, and for example, a three-dimensional culture model in which human normal epidermal cells are layered and cultured may be used. , EPISKIN (SkinEthic) etc. can be used.

本発明において「荷重を加える」とは、何らかの手段により培養表皮モデルに圧迫刺激を加える趣旨である。例えば、重りを載せる 、空気で加圧する、水で圧迫するなどの手段が挙げられる。その強弱は特に限定されない。培養表皮モデルに荷重刺激を与える方法については特に限定されない。培養表皮モデル全体に荷重を加えても良いし、一部に荷重を加えても良い。例えば、荷重をかけた際に細胞死が起こらない範囲内の重りを細胞に載せて刺激することが出来る。また、刺激を与える時間や間隔、回数についても限定されない。荷重刺激による遺伝子発現量の変化は刺激回数が増えるほど顕著になる一方で、培養表皮モデルは培養期間が長くなると通常培養した場合でも徐々に正常な角層機能が失われていくことが知られているため、これらの変化を考慮して条件を選択すれば良い。 In the present invention, "to apply a load" is intended to apply a compression stimulus to the cultured epidermis model by any means. For example, there are measures such as placing a weight, pressurizing with air, compressing with water, and the like. The strength is not particularly limited. There is no particular limitation on the method of applying load stimulation to the cultured epidermis model. A load may be applied to the whole culture epidermal model, or a part may be applied. For example, a weight within a range where cell death does not occur when a load is applied can be placed on cells for stimulation. In addition, the time, interval, and number of times to give stimulation are not limited. It is known that changes in gene expression level due to load stimulation become more pronounced as the number of stimulations increases, while the cultured epidermal model gradually loses its normal stratum corneum function even in normal culture when the culture period is extended Therefore, the conditions should be selected in consideration of these changes.

本発明において「指標にする」とは、例えば、遺伝子の発現量であれば、ケラチン1、ケラチン10より選択された1つ以上の遺伝子の発現量とインボルクリン遺伝子の発現量の変化量を指標にするという趣旨であり、「変化量」における「変化」は、発現量の増加、減少、変動しない場合も含む趣旨である。例えば、荷重刺激を与えた後の被験物質の有無(試験群・ブランク群)での比較でも良いし、被験物質存在下で荷重刺激を与えたもの(試験群)と被験物質無し・無刺激のもの(コントロール群)との比較でも良く、これらの比較によって当該被試験物質の有効性を決定することが出来る。「タンパク量を指標にする」場合も、これと同様に考えれば良い。
さらに、ケラチン1、ケラチン10、インボルクリン遺伝子の発現量のみを指標にする場合、ケラチン1、ケラチン10、インボルクリンのタンパクの発現量のみを指標にする場合以外に、ケラチン1、ケラチン10については遺伝子発現量、インボルクリンについてはタンパク発現量を指標にする場合、ケラチン1、ケラチン10についてはタンパク発現量、インボルクリンについては遺伝子発現量を指標にすることもできる。
In the present invention, “to be used as an indicator” means, for example, the expression amount of a gene, using the expression amount of one or more genes selected from keratin 1 and keratin 10 and the change amount of the expression amount of involucrin gene as an indicator “Change” in “amount of change” is intended to include the case where the amount of expression does not increase, decrease, or does not change. For example, a comparison may be made between the presence or absence of a test substance (test group · blank group) after subjecting to load stimulation, or one that a load stimulus was given in the presence of a test substance (test group) and no test substance · no stimulation It may be a comparison with a substance (control group), and the comparison can determine the efficacy of the test substance. In the case of using the amount of protein as an indicator, it may be considered similarly to this.
Furthermore, when using only the expression levels of keratin 1, keratin 10, and involucrin gene as an index, gene expression for keratin 1, keratin 10 is not the case where only the expression levels of keratin 1, keratin 10, and involucrin proteins are used as an index. For the amount and involucrin, when protein expression level is used as an indicator, for keratin 1 and keratin 10, protein expression level and for involucrin, gene expression level can be used as an index.

本発明において「発現量が減少する」とは、例えば、遺伝子の発現量の場合、試験群(荷重あり、かつ被験物質あり)とブランク群(荷重あり、かつ被験物質なし)を比較した際にその遺伝子発現量が減少していれば良い。減少の程度は求める効果の度合いによって適宜設定すれば良いが、試験群とブランク群を比較した際に好ましくは概ね10%、より好ましくは25%ぐらいの差があれば、より有効な効果物質を選択することが期待出来る。
「タンパク発現量が減少する」という場合も、同様の趣旨である。
In the present invention, "the amount of expression decreases" means, for example, in the case of the amount of gene expression, when a test group (with load and with a test substance) and a blank group (with load and with no test substance) are compared. The amount of expression of the gene may be reduced. The degree of reduction may be appropriately set according to the degree of effect to be obtained, but when the test group and the blank group are compared, if there is a difference of preferably about 10%, more preferably about 25%, a more effective effect substance It can be expected to choose.
Also in the case of "the amount of protein expression decreases", it is the same meaning.

本発明において「発現量に変化がない」とは数学的に全く変化がないという趣旨ではない。試験の一般的なバラつきを考慮して実質的に変化がないという趣旨である。具体的には、例えば遺伝子の発現量の場合、試験群とブランク群の遺伝子発現量を比較し、その差に実質的な差異が無ければ良い。試験の一般的なバラつきを考慮すると、その差が概ね±5%程度であれば、差がないと判断出来る目安となる。
「タンパクの発現量に変化がない」という場合も、同様の趣旨である。
In the present invention, "no change in the expression level" does not mean that there is no mathematical change at all. It means that there is substantially no change in consideration of the general variation of the test. Specifically, for example, in the case of the gene expression level, the gene expression levels of the test group and the blank group may be compared, and the difference may not be substantially different. Considering the general variation of the test, if the difference is approximately ± 5%, it is an indication that it can be judged that there is no difference.
Also in the case of "there is no change in the expression level of protein", the same purpose is obtained.

培養表皮モデルから遺伝子やタンパクを抽出する方法は公知の方法を用いれば良い。例えば、遺伝子の抽出であればRNeasy Mini Kit(Qiagen)などが使用でき、抽出された全RNAは必要に応じてさらにmRNAのみに精製して用いても良い。 A known method may be used as a method of extracting a gene or a protein from a cultured epidermal model. For example, in the case of gene extraction, RNeasy Mini Kit (Qiagen) or the like can be used, and the extracted total RNA may be further purified to mRNA only if necessary.

本発明の遺伝子発現量の確認方法は、公知の方法を用いれば良い。遺伝子チップ、アレイ等の固相化試料を用いた核酸ハイブリダイゼーション法、RT−PCR法、リアルタイムPCR法、サブトラクション法、ならびにクロスハイブリダイゼーション法など公知の方法を用いて測定することが出来る。 The method for confirming the gene expression level of the present invention may be a known method. It can measure using well-known methods, such as a nucleic acid hybridization method, RT-PCR method, real-time PCR method, subtraction method, and cross hybridization method using immobilized samples, such as a gene chip and an array.

タンパクの発現量を確認する場合は、ウエスタンブロット法、ELISA法、免疫沈降法など公知の方法を用いて測定することが出来る。   When confirming the expression level of protein, it can be measured using a known method such as Western blotting, ELISA, immunoprecipitation and the like.

本発明では、培養表皮モデルから作製した切片を用いて測定した角層の厚みの変化を指標とすることも出来る。角層の厚みの変化を単独で指標としても良いし、遺伝子発現やタンパク発現と合わせて指標にしても良い。複数のファクターを指標にすることで、より好ましい物質を選択することが出来る。   In the present invention, the change in the thickness of the stratum corneum measured using a section prepared from a cultured epidermis model can also be used as an index. Changes in the thickness of the stratum corneum may be used alone as an indicator, or may be used as an indicator together with gene expression or protein expression. By using a plurality of factors as indicators, more preferable substances can be selected.

被験物質は特に制限はない。動植物由来エキス、菌類の培養物またはこれらの酵素処理物、化合物またはその誘導体等であっても被験物質として用いることができ、液状の他、粉末状、ジェル状等であっても差し支えない。また、そのままでは培地に溶解しない場合は、界面活性剤等の可溶化剤を適宜使用することにより溶解させることで被験物質として用いることが出来る。さらに、抽出の方法も特に限定されない。添加濃度については、エキス等被験物質を添加してから24時間後に明らかに細胞が死滅していなければどの濃度でも問題ない。また、被験物質と培養表皮モデルとを共存させるステップは、培養表皮モデルに荷重刺激を与える前でも後でも、同時でも良い。被験物質と培養表皮モデルとを共存させる方法としては、被験物質を培養表皮モデルの培地側に添加する方法、角層側に添加する方法等が挙げられる。 The test substance is not particularly limited. Extracts from plants and animals, cultures of fungi or their enzyme-treated products, compounds or derivatives thereof can be used as test substances, and they may be powders, gels, etc. in addition to liquids. When it is not dissolved in the medium as it is, it can be used as a test substance by dissolving it by appropriately using a solubilizing agent such as a surfactant. Furthermore, the method of extraction is not particularly limited. With regard to the concentration to be added, any concentration may be used as long as the cells are not apparently killed 24 hours after the addition of the test substance such as the extract. In addition, the step of coexisting the test substance with the cultured epidermis model may be performed before, after, or simultaneously with applying load stimulus to the cultured epidermis model. Examples of the method for causing the test substance and the culture epidermis model to coexist include a method of adding the test substance to the culture medium side of the culture epidermis model, a method of adding the test substance to the stratum corneum side, and the like.

本発明のスクリーニング方法を用いたキットは当該方法を使用していれば特に限定はされない。一つのキットで本発明のスクリーニング方法を具備するものでも良いし、二つ以上のキットに分かれていても差し支えない。例えば、培養表皮モデルとこれに適した培地、使用する重りをセットにしたもの等が考えられる。 The kit using the screening method of the present invention is not particularly limited as long as the method is used. One kit may be equipped with the screening method of the present invention, or it may be divided into two or more kits. For example, a culture epidermal model, a medium suitable for this, a set of weights to be used, and the like can be considered.

以下、本発明を実施例によりさらに具体的に説明するが、本発明はこれらの実施例により限定されるものではない。   Hereinafter, the present invention will be more specifically described by way of examples, but the present invention is not limited by these examples.

<試験1>踵荒れと各種因子との関係
試験に同意を得た20歳〜40歳代の男女30名に対し、下記項目について皮膚測定試験を実施した。各測定は被験者の両足を33±2℃前後のぬるま湯で水洗し、10分間測定環境(23±2℃,5%RH)に馴化させた後に実施した。
<Test 1> Relationship between roughening and various factors The skin measurement test was carried out on the following items for 30 males and females aged 20 to 40 who obtained consent to the test. Each measurement was performed after washing the subject's feet with warm water at around 33 ± 2 ° C. and acclimating to the measurement environment (23 ± 2 ° C., 5% RH) for 10 minutes.

<測定項目と方法>
1.体重
各被験者の体重を体組成計(インナースキャンBC−202,TANITA)にて測定した。
2.皮膚の柔らかさ
足底の踵部中央を測定部位とし、被験者がベッドの上に伏臥位の体勢になり、ベッドの上面に対して足の甲が直角になる様に足先を垂らした状態で、踵部中央を硬度・弾性測定装置(BLS780 Ballistomer,DIA−STRON)にて数回測定し、k値が0.97〜1.03である3点のIndent値の平均値を算出し、これを皮膚の柔らかさとした。
3.表皮角層水分量
被験者が皮膚の柔らかさ測定と同様の体勢の状態で踵部中央を皮表角層水分量測定装置(SKICON−200EX−USB,YAYOI)にて7点測定し、上限値と下限値を除いた5点の平均値を算出し、これを表皮角層水分量とした。
4.経表皮水分蒸散量
被験者が皮膚の柔らかさ測定と同様の体勢の状態で踵部中央をポータブル水分蒸散計(VapoMeter,Delfin)にて3点測定し、平均値を算出して、これを経表皮水分蒸散量とした。
5.角層細胞面積
5−1.角層細胞の採取
被験者の踵部中央より角質チェッカー(角質チェッカー プラスチックプレートタイプ,PROMOTOOL)を用いて角層細胞を剥離した。
5−2.角層細胞面積の算出
採取した角層細胞をヘマトキシリン−エオシン染色した後、蛍光顕微鏡(BZ−X710 All−in−One Fluorescence Microscope,キーエンス)にて撮影し、撮影画像から画像処理ソフトウェア(ImageJ)にて一定区画内に存在する角層細胞面積の平均値を算出して、これを角層細胞面積とした。
6.荒れ評価
被験者の足底踵部をデジタル一眼レフカメラ(OLYMPUS PEN Lite E−PL6,OLYMPUS)にて撮影し、この画像を用いて15名の評価者が荒れ状態を目視にて表1に示す基準で6段階評価した。
<Measurement item and method>
1. Body Weight The weight of each subject was measured by a body composition meter (inner scan BC-202, TANITA).
2. With the center of the buttocks of the soft soles of the skin as the measurement site, the subject is in a prone position on the bed, with the toes hanging down so that the instep is perpendicular to the top of the bed Measure the center of the buttocks several times with a hardness / elasticity measuring device (BLS 780 Ballistomer, DIA-STRON), and calculate the average value of the Indent values of three points with ak value of 0.97 to 1.03, Was the softness of the skin.
3. Epidermal stratum corneum water content The subject measured seven points at the center of the buttocks with the skin stratum corneum water content measuring device (SKICON-200EX-USB, YAYOI) in a state similar to the measurement of skin softness, and the upper limit The average value of five points excluding the lower limit value was calculated and used as the epidermal stratum corneum moisture content.
4. Transepidermal water transpiration amount The subject measures the center of the buttocks with a portable moisture transpiration meter (VapoMeter, Delfin) in the same posture as skin softness measurement, calculates the average value, and transepidermis It was the amount of water evaporation.
5. Stratum corneum cell area 5-1. The stratum corneum cells were exfoliated from the center of the buttocks of the subjects from which stratum corneum cells were collected using a horny checker (keratin checker plastic plate type, PROMOTOOL).
5-2. Hematoxylin-eosin staining of the stratum corneum cell area was collected, and then photographed with a fluorescence microscope (BZ-X710 All-in-One Fluorescence Microscope, Keyence), and the photographed image was used as image processing software (Image J) The mean value of the stratum corneum cell area present in a certain compartment was calculated and used as the stratum corneum cell area.
6. Photographed by the digital single-lens reflex camera (OLYMPUS PEN Lite E-PL6, OLYMPUS) the footpad area of the rough evaluation subject, and the criteria by which 15 evaluators visually indicate rough conditions using Table 1 in Table 1 It rated it in six steps.

7.解析方法
荒れ評価の結果から図1に示すような皮膚状態を代表とする踵表面が滑らかな健常群(レベル0および1)と、表面に細かな亀裂や粉ふきが認められ全体にかさついた様相を示す荒れ群(レベル4および5)の2群を抽出し、各測定結果をこの2群で比較、評価した。
7. Analysis method From the result of the rough evaluation, the normal group (levels 0 and 1) with smooth eyelid surface represented by skin condition as shown in Fig. 1 and fine cracks and dust on the surface were found, and the whole was bulky Two groups of rough groups (levels 4 and 5) showing the appearance were extracted, and the measurement results were compared and evaluated in the two groups.

<結果と考察>
結果を図2〜図6に示す。図2〜6に示すように健常群と荒れ群では各測定項目において違う特徴を有することが確認された。
<Results and Discussion>
The results are shown in FIGS. As shown in FIGS. 2-6, it was confirmed that the healthy group and the rough group have different characteristics in each measurement item.

<体重>
踵における荒れ群では健常群と比べて、体重が重い傾向を示した。
頬や手の甲等における肌荒れは、一般に体重差に関係なく見られる現象である。踵における肌荒れは、荷重に起因している可能性が示唆された。
<Weight>
The rough group in the group showed a tendency to be heavier in weight than the normal group.
Rough skin on the cheeks, back of hands, etc. is a phenomenon generally seen regardless of weight differences. It was suggested that the rough skin in the eyelid may be due to the load.

<皮膚の柔らかさ>
踵における荒れ群では健常群に比べ皮膚が硬いことが認められた。
角層の水分量は皮膚の柔軟性に寄与していると言われていることから、水分量が少なく、硬く肥厚した皮膚は外部環境からの機械的刺激などに対して柔軟に対応することが出来ないため、弱い状態であると考えられ、その程度は異なるものの、頬や手の甲等における肌荒れでも同様の変化が起きていると予想される。
<Soft skin>
It was found that the rough skin in the rough skin is harder than the normal skin.
The water content of the stratum corneum is said to contribute to the softness of the skin, so it is possible that the skin with a small amount of water and hard and thickened can respond flexibly to mechanical irritation from the external environment, etc. Since it can not be done, it is considered to be in a weak state, and although the degree is different, it is expected that the same change occurs even in rough skin on the back of the cheek or the hand.

<経表皮水分蒸散量と表皮角層水分量>
踵における荒れ群では健常群と比べて、経表皮水分蒸散量は低く、表皮角層水分量が少ないことが確認された。一般に、頬や手の甲等における肌荒れでは、経表皮水分蒸散量が高く、表皮角層水分量が少ないことが知られているが、踵における肌荒れは、頬や手の甲等とは異なる現象が起きていることがわかった。
Transepidermal water loss and epidermal stratum corneum water content
It was confirmed that the amount of transepidermal water loss was lower and the amount of epidermal stratum corneum water content was lower in the rough group in the persimmon than in the healthy group. Generally, it is known that rough skin on the cheek and back of the hand has a high transepidermal water loss and a small amount of water in the stratum corneum, but rough skin on the eyelid has a different phenomenon than the back of the cheek or hand I understood it.

<角層細胞面積>
角層細胞面積は、踵における荒れ群では健常群と比べて大きくなる傾向が認められた。
一般に、ターンオーバーが正常な状態よりも早すぎると正常な角化が行われず、バリア機能が弱くなるため肌荒れを招くことが知られているが、踵では角層細胞面積が大きかったことから、ターンオーバーは遅く、通常の肌荒れとは異なる現象が起きていることがわかった。
<Corneal cell area>
The stratum corneum cell area tended to be larger in the rough group in the rat than in the normal group.
Generally, it is known that if the turnover is earlier than normal, normal keratinization will not be performed and the barrier function will weaken, leading to rough skin, but the area of stratum corneum is large in the eyelids, It was found that the turnover was slow and a phenomenon different from normal skin roughening had occurred.

<まとめ>
一般に、炎症等に起因してターンオーバーが速まった結果引き起こされる頬や手の甲等における肌荒れでは、バリア機能の低下により経表皮水分蒸散量が高く、角層水分量が少ないことが知られているが、上記結果から、踵における肌荒れではターンオーバーが遅く、経表皮水分蒸散量が低いのにも関わらず、角層水分量も少ないという一般的な肌荒れとは異なる特徴を有していることがわかった。また、荒れ群では体重が重く、皮膚も硬いことから日常的に体重という負荷(荷重)が繰り返されることにより、頬や手の甲等の肌荒れとは異なる荒れ現象が起きていることが示唆された。
<Summary>
In general, it is known that transepidermal water loss is high due to a decrease in barrier function and that the stratum corneum water content is low in rough skin on the cheek or back of hands caused as a result of accelerated turnover caused by inflammation etc. However, from the above results, although the turnover is slow in the rough skin in the eyebrows and the transepidermal water loss is low, it has characteristics different from the general rough skin that the stratum corneum water content is also small all right. Moreover, in the rough group, the weight is heavy, and the skin is also hard, so it is suggested that a rough phenomenon different from that of rough skin such as the cheek or the back of the hand is occurring because the load of the weight is repeated on a daily basis.

<試験2>培養表皮モデルを用いた荷重刺激実験
踵皮膚測定から踵の荒れの一因として荷重刺激による角層の肥厚が考えられたため、本発明者らは荷重刺激による角層肥厚の誘発について培養表皮モデルを用いて検討した。
<Test 2> Load Stimulation Experiment Using Cultured Epidermis Model Since thickening of the stratum corneum by load stimulation was considered as a factor of roughening of the eyelid skin measurement, the inventors of the present invention are about induction of stratum corneum thickness by load stimulation. The study was conducted using a cultured epidermal model.

<材料と方法>
1.培養表皮モデル
体重による踵への荷重刺激を再現する試験としてヒト正常表皮細胞を重層培養したヒト三次元培養表皮モデルであるLabCyte EPI−MODEL(ジャパン・ティッシュ・エンジニアリング)を用いた。
2.重り
培養表皮モデルへの荷重刺激はステンレス製のボルトとナットを組み合わせて作成した重りを用いた。
なお、重りは細胞に載せて刺激を加え、培養した際に細胞の生存数に影響を及ぼさないことをあらかじめ確認した上で重量を決定し、これを用いた。
3.培養表皮モデルへの荷重刺激
ヒト三次元培養表皮モデルLabCyte EPI−MODEL(ジャパン・ティッシュ・エンジニアリング)を37℃、5%CO下で培養し、2〜3日に1回アッセイ培地[EPI−MODEL](ジャパン・ティッシュ・エンジニアリング)の交換を行った。
踵皮膚における荷重刺激の再現として、培養表皮モデルに荷重刺激を与え、荷重刺激を与えた群と荷重刺激を与えない群とを比較することでその影響を確認した。荷重刺激を与える群では重り(約4.5g)を各皮膚モデルカップの上に30分間静置し、その後重りを取り除き、培地を交換後に培養を継続した。
培地交換から次の培地交換前までを1回の培養として、上記培養を5回繰り返した。
荷重刺激による遺伝子発現量変化は培養開始9日後に次の実験手法により測定した。
4.荷重刺激後の発現量変化の評価
培養後の培養表皮モデルはCell Counting Kit−8(同仁化学)を用いたWST−8により荷重刺激が細胞生存率に著しい影響を及ぼしていないことを確認した(図7)。
細胞生存率の確認後、リン酸緩衝生理食塩水(Ca、Mg不含)(Phosphate Buffered Saline、PBS(−))で皮膚モデルカップを洗浄し、カップからメスを用いて培養表皮モデルを切り離した。
切り離した細胞からRNeasy Mini Kit(Qiagen)を用いて細胞内の全RNA(総RNA)を分離・精製した。
分離・精製した全RNAから逆転写キットPrimeScriptTM RT Reagent Kit (Perfect Real Time)(タカラバイオ)を利用してcDNAを合成し、逆転写ポリメラーゼ連鎖反応(Reverse Transcription Polymerase Chain Reaction、RT-PCR)により複数の角化マーカーの遺伝子発現量を定量的に分析した。表2に各遺伝子発現量を定量するために用いたプライマーを記載する。プライマーはインビトロジェンに合成を依頼したものを購入して用いた。
荷重刺激を与えず培養のみ行った群(荷重なし)と荷重刺激を与えて培養した群(荷重あり)とを比較することで、荷重刺激による遺伝子発現量変化を評価した(図8〜10)。
<Materials and Methods>
1. LabCyte EPI-MODEL (Japan Tissue Engineering), which is a human three-dimensional cultured epidermal model in which human normal epidermal cells are cultured in a stratified manner, was used as a test to reproduce load stimulation to the eyelid by cultured epidermal model weight.
2. The load stimulation to a weight culture epidermal model used the weight created combining stainless steel bolts and nuts.
The weight was placed on the cells and stimulation was applied, and it was confirmed that it had no effect on the number of surviving cells when cultured, and then the weight was determined and used.
3. Load Stimulated Cultured Epidermis Model Human Three-Dimensional Cultured Epidermis Model LabCyte EPI-MODEL (Japan Tissue Engineering) is cultured at 37 ° C., 5% CO 2 , and once every 2-3 days Assay Medium [EPI-MODEL ] (Japan Tissue Engineering) was exchanged.
As a reproduction of the load stimulation in the eyelid skin, the culture skin model was given a load stimulation, and the effect was confirmed by comparing the group given the load stimulation with the group not given the load stimulation. In the load stimulation group, weights (about 4.5 g) were placed on each skin model cup for 30 minutes, after which the weights were removed and culture was continued after replacing the medium.
The above culture was repeated five times, from the medium replacement to the next medium replacement as one culture.
The gene expression level change due to load stimulation was measured by the following experimental method 9 days after the start of culture.
4. Evaluation of changes in expression level after load stimulation The cultured epidermis model after culture confirmed that load stimulation had no significant effect on cell viability by WST-8 using Cell Counting Kit-8 (Dojin Kagaku) Figure 7).
After confirmation of cell viability, the skin model cup was washed with phosphate buffered saline (Ca, Mg free) (Phosphate Buffered Saline, PBS (-)), and the cultured epidermis model was separated using a female from the cup .
Total RNA (total RNA) in cells was separated and purified from the separated cells using RNeasy Mini Kit (Qiagen).
From total RNA isolated and purified by using a reverse transcription kit PrimeScript TM RT Reagent Kit (Perfect Real Time) ( Takara Bio) were synthesized cDNA, by reverse transcription polymerase chain reaction (Reverse Transcription Polymerase Chain Reaction, RT -PCR) The gene expression levels of several keratinization markers were analyzed quantitatively. Table 2 describes the primers used to quantify each gene expression level. The primers used were purchased from Invitrogen for synthesis.
Changes in gene expression level due to load stimulation were evaluated by comparing the group in which only culture was performed without load stimulation (without load) with the group in which load stimulation was performed (with load) (FIGS. 8 to 10). .

<結果と考察>
遺伝子発現量の評価では培養表皮モデルに対して重りを一定時間のせ荷重刺激を与えることで角化マーカーのケラチン1及びケラチン10の遺伝子発現量が増加するのに対して(図8、図9)、インボルクリンでは増加しておらず(図10)、無刺激で通常培養した正常な培養表皮モデルとは異なる遺伝子発現の傾向であることを確認した。
無刺激で通常培養した場合、培養表皮モデルでは正常に角化が進み、十分なバリア機能を有した角層が形成されることが知られている。
すなわち、実験の結果は荷重刺激によって角化過程における角化マーカーの遺伝子発現量に変化が起こり、乱れが生じたことを表していると言える。
<Results and Discussion>
In the evaluation of the gene expression level, by applying weight stimulation to the cultured epidermis model for a fixed time, the gene expression levels of keratinization markers keratin 1 and keratin 10 are increased (Fig. 8, Fig. 9). It was confirmed that there was no increase in involucrin (FIG. 10), and that there was a tendency for gene expression different from that of a normal cultured epidermal model normally cultured without stimulation.
It is known that when cultured without stimulation, keratinization proceeds normally in the cultured epidermis model, and a stratum corneum having a sufficient barrier function is formed.
That is, it can be said that the result of the experiment indicates that the gene expression amount of the keratinization marker in the keratinization process is changed by the load stimulation, and the disturbance is generated.

5.角層厚測定による角層肥厚の評価
培養表皮モデルに荷重刺激を加える、あるいは刺激を加えずに一定期間培養を行った後、皮膚モデルカップからメスを用いて培養表皮モデルを切り離した。
切り離した培養表皮モデルをO.C.T.コンパウンド(サクラファインテックジャパン)で包埋し、これを急速凍結した。
凍結した細胞はクリオスタッド(Leica Microsystems)を用いて薄切し、切片を作製した。
切片はマイルドホルム(和光純薬)を用いて固定した。
ヘマトキシリン−エオシン染色にて細胞質および細胞核の染色を行った。
染色後の切片は蛍光顕微鏡(キーエンス)を用いて撮影し、撮影画像を用いてフリーの画像処理ソフトウェア(ImageJ)にて角層厚の計測を行い、計測結果を比較して角層厚の変化を評価した。
5. Evaluation of stratum corneum thickening by stratum corneum layer thickness measurement After applying a load stimulus to the cultured epidermal model or culturing for a fixed period without applying a stimulus, the cultured epidermal model was separated from the skin model cup using a scalpel.
The isolated culture epidermis model is C. T. It was embedded with a compound (Sakura Finetech Japan) and it was rapidly frozen.
Frozen cells were sectioned using Cryostad (Leica Microsystems) and sectioned.
The sections were fixed using mildform (Wako Pure Chemical Industries, Ltd.).
Staining of cytoplasm and cell nucleus was performed by hematoxylin-eosin staining.
The sections after staining are photographed using a fluorescence microscope (Keyence), and the angular layer thickness is measured using free image processing software (ImageJ) using the photographed image, and the measurement results are compared to change the angular layer thickness. Was evaluated.

結果を図11に示す。
図11に示すように荷重ありの表皮培養モデルの角層厚は荷重なしと比べて優位に増加していた。
The results are shown in FIG.
As shown in FIG. 11, the angular layer thickness of the epidermal culture model with load was increased significantly compared to no load.

角層厚の評価でも荷重刺激によって角層厚が増加することを確認したことから、この変化は角化マーカーの遺伝子発現量の変化に伴い生じたものであると考えられた。 Since it was confirmed that the stratum corneum layer thickness was increased by load stimulation also in the evaluation of the stratum corneum layer thickness, it was considered that this change occurred with the change in gene expression amount of the keratinization marker.

実際のヒト踵の皮膚では上記実験で用いた重りの細胞に対する荷重刺激よりも大きな刺激が加わっていると予想され、踵の角層ではよりダイナミックに角化過程における遺伝子発現量の変化が起きていると考えられる。また、角層厚についても遺伝子発現量の変化に伴って厚みが増加することで踵の角層は肥厚した状態になっていると予想された。   It is expected that in human skin of human eyelids, stimulation larger than that of weight stimulation to cells used in the above experiment is applied, and in the horny layer of eyelids, gene expression changes during the keratinization process occur more dynamically It is thought that In addition, it was predicted that the stratum corneum of the eyebrow was in a thickened state as the thickness also increased with changes in gene expression level with respect to the stratum corneum layer thickness.

前述の踵皮膚測定試験の結果と培養表皮モデルを用いた荷重刺激実験の結果から、荒れた踵の皮膚では過剰な荷重刺激によって角化過程に関連する遺伝子発現に変化が起きることで角層の肥厚を誘発し、その結果、角層への水分供給不足やNMF、セラミドなどの保湿因子の流出が起こり、荒れを誘発していると考えられた。
すなわち過剰な荷重刺激による遺伝子発現の変化を抑制することが出来れば、角層の肥厚を防止、改善することが可能となり、角層の肥厚に起因した荒れの誘発を防ぐことが出来る。
言い換えれば、荷重刺激によって起こる特にケラチン1やケラチン10の遺伝子発現量の増加を防ぎ、正常な状態と同じ発現量にすることで荒れの誘発を防止することが出来ると言える。
From the results of the above-mentioned vaginal skin measurement test and the results of the load stimulation experiment using the cultured epidermis model, in the rough skin of the rabbit, changes in gene expression related to the keratinization process are caused by excessive load stimulation. It was thought that thickening was induced, and as a result, lack of water supply to the stratum corneum and outflow of moisturizing factors such as NMF and ceramide occurred to induce roughening.
That is, if changes in gene expression due to excessive load stimulation can be suppressed, thickening of the stratum corneum can be prevented and improved, and the induction of roughness caused by thickening of the stratum corneum can be prevented.
In other words, it can be said that the increase in gene expression levels of keratin 1 and keratin 10 caused by load stimulation can be prevented, and rough expression can be prevented by using the same expression level as in the normal state.

<培養表皮モデルを用いたスクリーニング例>
1.ヒト三次元培養表皮モデルLabCyte EPI−MODEL(ジャパン・ティッシュ・エンジニアリング)を37℃、5%CO下で培養し、2〜3日に1回アッセイ培地[EPI−MODEL](ジャパン・ティッシュ・エンジニアリング)の交換を行った。
2.荷重刺激を与える群では重り(約4.5g)を各皮膚モデルカップの上に30分間静置し、その後重りを取り除き、培地を交換後に培養を継続した。
3.被験物質(市販の植物エキス)は、初回の刺激のみ荷重刺激を与える前の培地に終濃度50ppmあるいは100ppmとなる様に添加し、2回目以降は、重り(約4.5g)を各皮膚モデルカップの上に30分間静置し、その後重りを取り除き、培地を交換する際に適当な終濃度になるよう被験物質を添加した後、培養を継続した。
培地交換から次の培地交換前までを1回の培養として、上記培養を5回繰り返した。
4.荷重刺激による遺伝子発現量の変化は培養開始9日後に次の実験手法により測定した。
<Example of screening using cultured epidermal model>
1. Human three-dimensional cultured epidermal model LabCyte EPI-MODEL (Japan Tissue Engineering) is cultured at 37 ° C., 5% CO 2 , and once every 2-3 days assay medium [EPI-MODEL] (Japan Tissue Engineering) Made a replacement.
2. In the load stimulation group, weights (about 4.5 g) were placed on each skin model cup for 30 minutes, after which the weights were removed and culture was continued after replacing the medium.
3. The test substance (commercially available plant extract) is added to the medium before the first stimulation only to give a load stimulation to a final concentration of 50 ppm or 100 ppm, and after the second time, a weight (about 4.5 g) is added to each skin model After standing for 30 minutes on the cup, after removing the weight and adding a test substance to achieve an appropriate final concentration when changing the medium, the culture was continued.
The above culture was repeated five times, from the medium replacement to the next medium replacement as one culture.
4. The change in gene expression level due to load stimulation was measured by the following experimental method 9 days after the start of culture.

<荷重刺激後の発現量変化の評価>
1.培養後のヒト三次元培養表皮モデルはCell Counting Kit−8(同仁化学)を用いたWST−8により荷重刺激が細胞生存率に著しい影響を及ぼしていないことを確認した。
2.細胞生存率の確認後、リン酸緩衝生理食塩水(Ca、Mg不含)(Phosphate Buffered Saline、PBS(−))で皮膚モデルカップを洗浄し、カップからメスを用いてヒト三次元培養表皮モデルを切り離した。
3.切り離した細胞からRNeasy Mini Kit(Qiagen)を用いて細胞内の全RNA(総RNA)を分離・精製した。
4.分離・精製した全RNAから逆転写キットPrimeScriptTM RT Reagent Kit (Perfect Real Time)(タカラバイオ)を利用してcDNAを合成し、逆転写ポリメラーゼ連鎖反応(Reverse Transcription Polymerase Chain Reaction、Q−RT-PCR)により複数の角化マーカーの遺伝子発現量を定量的に分析した。各遺伝子発現量を定量するために表1に記載したプライマーを用いた。プライマーはインビトロジェンに合成を依頼したものを購入して用いた。
5.被験物質を培地に添加した群(試験群)と添加していない群(ブランク群)とを比較し、さらに荷重なし、被験物質なしで培養のみ行った群(コントロール群)とも比較することで、被験物質の踵荒れ抑制効果を評価した。より高い効果を有する物質を選択する為、試験群とブランク群とを比較した場合にケラチン1またはケラチン10より選択された少なくとも1つ以上の遺伝子発現量を10%以上減少させ、且つ、インボルクリンの遺伝子発現量は±5%程度の変化に留めるような被験物質を目安に踵荒れ抑制効果を有する物質と判断した。
<Evaluation of expression change after load stimulation>
1. The human three-dimensional cultured epidermal model after culture was confirmed by WST-8 using Cell Counting Kit-8 (Dojin Kagaku) that load stimulation did not significantly affect cell viability.
2. After confirmation of cell viability, the skin model cup is washed with phosphate buffered saline (Ca, Mg free) (Phosphate Buffered Saline, PBS (-)), and a human three-dimensional cultured epidermal model using a female from the cup Separated.
3. Total RNA (total RNA) in cells was separated and purified from the separated cells using RNeasy Mini Kit (Qiagen).
4. Reverse transcription kit from total RNA isolated and purified PrimeScript TM RT Reagent Kit (Perfect Real Time) by utilizing (Takara Bio) were synthesized cDNA, reverse transcription polymerase chain reaction (Reverse Transcription Polymerase Chain Reaction, Q -RT-PCR The gene expression levels of several keratinization markers were analyzed quantitatively by The primers described in Table 1 were used to quantify each gene expression level. The primers used were purchased from Invitrogen for synthesis.
5. By comparing the group (test group) to which the test substance was added to the culture medium (test group) and the group (blank group) to which the test substance was not added, and also comparing with the group without culture and only culture without test substance (control group), The roughening inhibitory effect of the test substance was evaluated. In order to select a substance having a higher effect, the expression level of at least one or more genes selected from keratin 1 or keratin 10 is reduced by 10% or more when the test group and the blank group are compared, and The amount of gene expression was determined to be a substance having a roughening inhibitory effect on the basis of a test substance whose change was limited to about ± 5%.

本発明によれば、踵特有の荒れ肌を抑制する効果を有する物質を選択することができ、踵における荒れ肌を根本的に解決出来る有効物質を提供することが期待される。



According to the present invention, it is expected that a substance having an effect of suppressing rough skin peculiar to eyebrows can be selected, and an effective substance capable of fundamentally solving rough skin in eyebrows can be provided.



Claims (6)

次の(A)〜(D)のステップを含む踵荒れ抑制効果を有する物質をスクリーニングする方法。
(A):培養表皮モデルと被験物質を共存させるステップ
(B):培養表皮モデルに荷重を加えるステップ
(C):培養表皮モデルから遺伝子又はタンパクを抽出するステップ
(D):(d−1)及び(d−2)を指標に踵荒れ抑制効果を有する物質を判断するステップ
(d−1):ケラチン1、ケラチン10より選択された少なくとも1つ以上の遺伝子発現量及び/又はタンパク発現量、
(d−2):インボルクリンの遺伝子発現量及び/又はタンパク発現量
The method of screening the substance which has the roughening control effect containing the step of following (A)-(D).
(A): A step of coexistence of a cultured epidermal model and a test substance
(B): applying a load to the cultured epidermal model (C): extracting a gene or protein from the cultured epidermal model
(D): (d-1) and (d-2) determining the substance having a roughening inhibitory effect with the index (d-1): at least one or more genes selected from keratin 1, keratin 10 Expression level and / or protein expression level,
(D-2): gene expression amount and / or protein expression amount of involucrin
(D)ステップにおいて、ケラチン1、ケラチン10より選択された少なくとも1つ以上の遺伝子発現量を減少させ、インボルクリンの遺伝子発現量は変化させない被験物質を踵荒れ抑制効果を有する物質として判断する請求項1記載のスクリーニング方法。 (D) In the step, a test substance which decreases the expression level of at least one or more genes selected from keratin 1 and keratin 10 and does not change the expression level of involucrin is determined as a substance having a roughening inhibitory effect. The screening method of 1. 次の(A)〜(D)のステップを含む踵荒れ抑制効果を有する物質をスクリーニングする方法。
(A):培養表皮モデルと被験物質を共存させるステップ
(B):培養表皮モデルに荷重を加えるステップ
(C):培養表皮モデルからタンパクを抽出するステップ
(D):ケラチン1、ケラチン10より選択された少なくとも1つ以上のタンパクの発現量及びインボルクリンのタンパクの発現量を指標に踵荒れ抑制効果を有する物質を判断するステップ
The method of screening the substance which has the roughening control effect containing the step of following (A)-(D).
(A): A step of coexistence of a cultured epidermal model and a test substance
(B): Step of applying a load to the cultured epidermis model (C): step of extracting a protein from the cultured epidermis model
(D): a step of determining a substance having a roughening inhibitory effect by using the expression level of at least one or more proteins selected from keratin 1 and keratin 10 and the expression level of protein of involucrin as an index
(D)ステップにおいて、ケラチン1、ケラチン10より選択された少なくとも1つ以上のタンパク発現量を減少させ、インボルクリンのタンパク発現量は変化させない被験物質を踵荒れ抑制効果を有する物質として判断する請求項3記載のスクリーニング方法。 (D) In the step, a test substance which decreases the expression level of at least one protein selected from keratin 1 and keratin 10 and does not change the expression level of protein of involucrin is judged as a substance having a roughening inhibitory effect. The screening method of 3. 次の(A)〜(C)のステップを含む踵荒れ抑制効果を有する物質をスクリーニングする方法。
(A):培養表皮モデルと被験物質を共存させるステップ
(B):培養表皮モデルに荷重を加えるステップ
(C):培養表皮モデルから組織切片を作製し、角層の厚みの変化を指標に踵荒れ抑制効果を有する物質を判断するステップ
The method of screening the substance which has the roughening control effect containing the step of following (A)-(C).
(A): A step of coexistence of a cultured epidermal model and a test substance
(B): A step of applying a load to a cultured epidermal model (C): A tissue section is prepared from the cultured epidermal model, and a step of judging a substance having a roughening inhibitory effect by using a change in stratum corneum thickness as an index
請求項1乃至請求項5記載の方法を用いた評価キット。

An evaluation kit using the method according to any one of claims 1 to 5.

JP2018003097A 2018-01-12 2018-01-12 Screening method and kit for heel roughness inhibitor Active JP7059015B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018003097A JP7059015B2 (en) 2018-01-12 2018-01-12 Screening method and kit for heel roughness inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018003097A JP7059015B2 (en) 2018-01-12 2018-01-12 Screening method and kit for heel roughness inhibitor

Publications (2)

Publication Number Publication Date
JP2019122266A true JP2019122266A (en) 2019-07-25
JP7059015B2 JP7059015B2 (en) 2022-04-25

Family

ID=67396988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018003097A Active JP7059015B2 (en) 2018-01-12 2018-01-12 Screening method and kit for heel roughness inhibitor

Country Status (1)

Country Link
JP (1) JP7059015B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021156731A (en) * 2020-03-27 2021-10-07 株式会社ナリス化粧品 Method for evaluating moisture retention capacity of horny layer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013134087A (en) * 2011-12-26 2013-07-08 Shiseido Co Ltd Cosmetic material evaluation method
JP2014204711A (en) * 2013-03-19 2014-10-30 国立大学法人 千葉大学 Method for production of three-dimensional culture skin model, and use thereof
WO2015132917A1 (en) * 2014-03-05 2015-09-11 株式会社資生堂 Method for screening skin barrier function-enhancing drug and method for evaluating skin barrier function having epidermal serine racemase and/or d-serine quantity as indicator
JP2017067612A (en) * 2015-09-30 2017-04-06 株式会社ナリス化粧品 Method and kit for screening material

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013134087A (en) * 2011-12-26 2013-07-08 Shiseido Co Ltd Cosmetic material evaluation method
US20150093772A1 (en) * 2011-12-26 2015-04-02 Shiseido Company, Ltd. Method for evaluating cosmetic
JP2014204711A (en) * 2013-03-19 2014-10-30 国立大学法人 千葉大学 Method for production of three-dimensional culture skin model, and use thereof
WO2015132917A1 (en) * 2014-03-05 2015-09-11 株式会社資生堂 Method for screening skin barrier function-enhancing drug and method for evaluating skin barrier function having epidermal serine racemase and/or d-serine quantity as indicator
JP2017067612A (en) * 2015-09-30 2017-04-06 株式会社ナリス化粧品 Method and kit for screening material

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021156731A (en) * 2020-03-27 2021-10-07 株式会社ナリス化粧品 Method for evaluating moisture retention capacity of horny layer
JP7024003B2 (en) 2020-03-27 2022-02-22 株式会社ナリス化粧品 Method for evaluating the water retention capacity of the stratum corneum

Also Published As

Publication number Publication date
JP7059015B2 (en) 2022-04-25

Similar Documents

Publication Publication Date Title
Lee et al. A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification
Danby Biological variation in skin barrier function: from A (atopic dermatitis) to X (xerosis)
Luebberding et al. Skin physiology in men and women: in vivo evaluation of 300 people including TEWL, SC hydration, sebum content and skin surface pH
Alleles Heterozygous null alleles in filaggrin contribute to clinical dry skin in young adults and the elderly
RU2493834C2 (en) Softening composition
JP6073238B2 (en) Screening method for skin cell differentiation promoting substance
Shiva et al. Evaluation of uric acid, total antioxidant and lipid peroxidation parameters in serum and saliva of patients with oral lichen planus
TWI580964B (en) Method for evaluating stress accumulation degree of skin
US10718782B2 (en) Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator
US20200363428A1 (en) Diagnostic method of a skin showing signs of aging
JP2019122266A (en) Screening method and kit of heel roughening suppression agent
US11193941B2 (en) Method for evaluating condition of skin dryness
CN108333362B (en) Human body fatigue measuring method
JP5653783B2 (en) Evaluation method of water retention ability in skin epidermis
JP7466721B2 (en) Improves skin barrier function caused by stress
JP5775540B2 (en) Evaluation method of UV stress applied by UV irradiation of skin
JP2015024968A (en) Selection method of cosmetics
Ebrahim et al. Ischemic Modified Albumin as A Biomarker in Predicting Oxidative Stress in Patients With Acne Vulgaris
Mohammadi et al. In Vitro Enzymatic Virulence Factors of Dermatophytes Species Isolated From Clinical Specimens
JP2010115178A (en) Method of forecasting skin inflammation and application of the same
Bedewi et al. Role of tissue liver X-receptors level in skin diseases
JP2011083207A (en) Method for evaluating epidermal turnover and application thereof
JP2010200971A (en) Method for predicting/estimating abnormal hair loss, precaution/prevention method for abnormal hair loss, and method for evaluating abnormal hair loss preventive agent
Hoste et al. Caspase-14 is a crucial protease in proper stratum corneum formation
Mohammad et al. Outcome of Patch Test on Crack Sole among Bangladeshi Population

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20180205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220413

R150 Certificate of patent or registration of utility model

Ref document number: 7059015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150